@drlisakoche's peptide therapy claims need context

What did @drlisakoche actually say?

The video makes four specific claims: that GLP-1 receptor agonists reduce inflammation (not just body weight), that BPC-157 addresses inflammation across the gut, tendons, joints, and "all over the body," and that LL-37 and TB-500 (TB4) act as immune modulators that can "fight infections" or restore immune balance. The framing is that chronic inflammation is often the root cause, and these peptides address it directly.

This is a condensed but substantive set of claims. It is not pure hype, but it is not the full picture either. The leap from early-phase research to "helps with everything" is where the video starts running ahead of the evidence.

Does the science back this up?

Partially, yes. The GLP-1 inflammation angle is the strongest claim here and it holds up reasonably well. BPC-157 has interesting preclinical data but almost no human trials. LL-37 and TB-500 are the shakiest, at least for clinical application right now.

On GLP-1s: multiple peer-reviewed papers have found anti-inflammatory signaling independent of weight loss. Drucker (2022, Cell Metabolism) reviewed GLP-1 receptor activity in immune cells and found suppression of NF-kB pathways and reduced circulating interleukins in rodent models, with some supporting human data from semaglutide trials. The SELECT cardiovascular trial (Lincoff et al., 2023, NEJM) found reduced C-reactive protein in people on semaglutide regardless of weight lost, which is real and notable.

BPC-157 is more complicated. Animal studies are plentiful. Sikiric et al. have published extensively on gut mucosal protection and tendon healing in rats. But as of 2024, there are no completed, peer-reviewed randomized controlled trials in humans. "Helps with everything" is not a scientific claim, it is a sales pitch.

LL-37 is a human cathelicidin with real immunomodulatory properties studied in wound healing and infection contexts (Vandamme et al., 2012, Drug Discovery Today). TB-500, a synthetic fragment of thymosin beta-4, has cardiac and tissue repair data in animal models. Neither has robust human clinical trial evidence for systemic inflammation management.

What did they get wrong (or right)?

The GLP-1 call is correct and deserves credit. Most people still think of semaglutide or tirzepatide as weight drugs, and the anti-inflammatory receptor activity is real science that is underreported in mainstream content.

The BPC-157 section is where the video overshoots. Saying it "helps with everything from inflammation in your gut to... joints, and all over the body" collapses a preclinical hypothesis into a clinical fact. That is misleading, even if the mechanism is plausible. The FDA has flagged BPC-157 as a substance that cannot be used in compounded preparations under current guidance, which is a material fact the video omits entirely.

Calling LL-37 and TB-500 "immune modulators" is technically fair. That descriptor fits the research. But framing them as solutions to the root cause of inflammation, without mentioning that this is largely theoretical in humans, gives viewers a false sense of clinical certainty. The "getting your immune system back in balance" framing is vague in a way that slides past scrutiny without actually saying anything falsifiable.

What should you actually know?

If you are exploring peptides for inflammation, the evidence quality varies enormously across this list, and that matters for how you think about risk versus benefit.

• GLP-1 receptor agonists have the strongest human evidence for anti-inflammatory effects. If you are already using one for metabolic reasons, the inflammation data is a legitimate secondary benefit to discuss with your provider.
• BPC-157 remains investigational. It is not FDA-approved for any indication. Compounded versions exist in a legal gray area, and the FDA has specifically raised concerns about its inclusion in compounded products. Anyone offering it should be transparent about that.
• LL-37 and TB-500 are research peptides. The mechanism is interesting. The human trial data is thin. "Immune modulator" sounds precise but covers a wide range of unproven effects.
• Chronic inflammation has many causes, including diet, sleep, metabolic dysfunction, and autoimmune conditions. No peptide stack addresses all of them, and no single video should give you enough confidence to self-prescribe.

The video is not reckless, but it does flatten the evidence in a way that serves enthusiasm over accuracy. Seek care from a provider who can order inflammatory markers, review your case, and discuss these options honestly, including what we do not yet know.